Eleven days. That is how long it took for aggressive lymphoma tumors to vanish in mice treated with a new experimental compound, according to researchers at Stanford Medicine. No surgery, no radiation—just a molecule small enough to slip inside a cell and clever enough to rewrite its instructions. The target is a protein called BCL6, one of the chief culprits behind diffuse large B-cell lymphoma, the most common form of non-Hodgkin lymphoma.

In healthy immune cells, BCL6 is a useful opportunist. It temporarily silences genes that would otherwise stop cells from multiplying or push them toward death, buying time for the immune system to mount a response. Once the threat passes, other proteins step in to switch BCL6 off, and the excess cells quietly self-destruct through apoptosis, the body's tidy mechanism for clearing out what it no longer needs. In lymphoma, that switch gets stuck.

BCL6 stays permanently active, and the death genes stay permanently muted—a biological jam that lets cancer cells multiply unchecked. Rather than simply blocking BCL6, the Stanford team, led by Gerald Crabtree and Nathanael Gray along with collaborators at MD Anderson Cancer Center, built a two-part molecule that physically tethers BCL6 to a separate protein capable of triggering cell death. In effect, the cancer's own engine is wired to its own kill switch. Twice-daily doses in mice were enough to make tumors disappear within days, a result the team sees as proof of concept for a much broader idea: using a disease's driving force as the very tool that dismantles it.